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                                      Worldwide, more than 2 billion people have been infected with 
hepatitis B virus (HBV) and approximately 350 million remain 
chronically infected (  1  ). Individuals with chronic HBV infection are 
Gastroenterology, Kaohsiung Chang-Gung Memorial Hospital, Kaohsiung, 
Taiwan (SNL); Chang-Gung Memorial Hospital and Chang-Gung University, 
Taoyuan, Taiwan (YFL)  .     
    Correspondence to:   Chien-Jen Chen, ScD, Genomics Research Center, 
Academia Sinica, 128 Academia Road, Section 2, Nankang, Taipei 11529, 
Taiwan (e-mail:   cjchen@ntu.edu.tw  ).   
      See   “Funding” and “Notes” following “References.”   
      DOI:   10.1093/jnci/djn243   
    © Oxford University Press 2008.
  This is an Open Access article distributed under the terms of the Creative Com  -
mons Attribution Non-Commercial License (http://creativecommons.org/licenses/ 
  by-nc/2.0/uk/), which permits unrestricted non-commercial use, distribution, and 
reproduction in any medium, provided the original work is properly cited.     
    ARTICLE   
          Associations Between Hepatitis B Virus Genotype 
and Mutants and the Risk of Hepatocellular 
Carcinoma   
        Hwai-I         Yang      ,           Shiou-Hwei         Yeh      ,           Pei-Jer         Chen      ,           Uchenna H.           Iloeje      ,           Chin-Lan         Jen      ,           Jun         Su      ,           Li-Yu         Wang      ,        
  Sheng-Nan         Lu      ,           San-Lin         You      ,           Ding-Shinn         Chen      ,           Yun-Fan         Liaw      ,           Chien-Jen         Chen
      For the REVEAL-HBV Study Group                                 
     Background     The risk of hepatocellular carcinoma (HCC) increases with increasing level of hepatitis B virus (HBV) in 
serum (viral load). However, it is unclear whether genetic characteristics of HBV, including HBV genotype 
and specific genetic mutations, contribute to the risk of HCC. We examined the HCC risk associated with 
HBV genotypes and common variants in the precore and basal core promoter (BCP) regions.   
     Methods     From January 5, 1991, to December 21, 1992, baseline blood samples were collected from 2762 Taiwanese 
men and women who were seropositive for HBV surface antigen but had not been diagnosed with HCC; 
the samples were tested for HBV viral load by real-time polymerase chain reaction and genotyped by 
melting curve analysis. Participants who had a baseline serum HBV DNA level greater than 10 
4   copies/mL 
(n = 1526) were tested for the precore G1896A and BCP A1762T/G1764A mutants by direct sequencing. 
Incident cases of HCC were ascertained through follow-up examinations and computerized linkage to the 
National Cancer Registry and death certification profiles. A Cox proportional hazards model was used to 
estimate the risk of HCC associated with HBV genotype and precore and BCP mutants after adjustment for 
other risk factors. All statistical tests were two-sided.   
     Results     A total of 153 HCC cases occurred during 33    847 person-years of follow-up. The HCC incidence rates per 
100    000 person-years for participants infected with HBV genotype B or C were 305.6 (95% confidence inter-
val [CI] = 236.9 to 388.1) and 785.8 (95% CI = 626.8 to 972.9), respectively. Among participants with a base-
line HBV DNA level of at least 10 
4   copies/mL, HCC incidence per 100    000 person-years was higher for those 
with the precore G1896 (wild-type) variant than for those with the G1896A variant (955.5 [95% CI = 749.0 
to 1201.4] vs 269.4 [95% CI = 172.6 to 400.9]) and for those with the BCP A1762T/G1764A double mutant 
than for those with BCP A1762/G1764 (wild-type) variant (1149.2 [95% CI = 872.6 to 1485.6] vs 358.7 [95% 
CI = 255.1 to 490.4]). The multivariable-adjusted hazard ratio of developing HCC was 1.76 (95% CI = 1.19 
to 2.61) for genotype C vs genotype B, 0.34 (95% CI = 0.21 to 0.57) for precore G1896A vs wild type, and 
1.73 (95% CI = 1.13 to 2.67) for BCP A1762T/G1764A vs wild type. Risk was highest among participants 
infected with genotype C HBV and wild type for the precore 1896 variant and mutant for the BCP 1762/1764 
variant (adjusted hazard ratio = 2.99, 95% CI = 1.57 to 5.70,   P   < .001).   
     Conclusions     HBV genotype C and specific alleles of BCP and precore were associated with risk of HCC. These associa-
tions were independent of serum HBV DNA level.   
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at increased risk of developing end-stage liver disease (including 
cirrhosis, hepatic failure, and hepatocellular carcinoma [HCC]), 
with a cumulative lifetime incidence of 15%  –  40% (  2  ,  3  ). Other 
important risk factors for HCC include the presence of hepatitis 
B virus e antigen (HBeAg)  —  a surrogate marker of active viral 
replication  —  and the amount of HBV (ie, viral load) in serum (  4  ,  5  ). 
Several reports (  6    –    9  ) have also suggested that the genetic character-
istics of HBV, including HBV genotype and specific genetic muta-
tions, are associated with the development of HCC. 
  Eight HBV genotypes (designated A through H) have been 
identiﬁ   ed, and most display a distinct geographic distribution 
(  10  ,  11  ). Genotypes B and C are the predominant HBV genotypes 
in Eastern Asia, including Taiwan (  7  ). Clinically important differ-
ences in outcomes are associated with the different HBV genotypes. 
HBV genotype C infection has been associated with later occurring 
and lower rates of spontaneous clearance of HBeAg in serum com-
pared with HBV genotype B infection (  12    –    15  ). In addition, geno-
type C is associated with higher levels of HBV DNA replication, 
more advanced liver disease, and a decreased rate of response to     -
interferon therapy compared with genotype B (  7  ,  9  ,  12  ,  13  ,  15    –    17  ). 
  HBV is a DNA virus that contains four overlapping open read-
ing frames that encode the surface (viral envelope), core (nucleo-
capsid), X (a nonstructural protein that operates as a multifunctional 
regulator modulating gene transcription, cell responses to geno-
toxic stress, protein degradation, apoptosis, and several signaling 
pathways), and polymerase proteins. The basal core promoter 
(BCP), which is located in the overlapping X open reading frame, 
controls transcription of both the precore and core regions. The 
precore region encodes the precore protein, which is processed in 
the endoplasmic reticulum to produce secreted HBeAg. HBV can 
evolve distinct variants that tend to cluster in the precore and BCP 
regions (  18  ,  19  ). Mutations in the precore region, which were the 
ﬁ  rst major common variants of HBV to be discovered (  20  ), are ﬁ  rst 
detectable around the time of HBeAg seroconversion and include 
mutations that prevent HBeAg synthesis without interfering with 
the production of infectious virions. The most common of these 
mutations is a G to A substitution at nucleotide 1896 (G1896A), 
which prevents the production of HBeAg by introducing a prema-
ture stop codon into the open reading frame of the precore region. 
This mutation (hereafter referred to as precore G1869A) is fre-
quently detected in patients with HBeAg-  negative chronic hepati-
tis B and in some patients with fulminant hepatitis B (  21    –    23  ). 
  The other common class of HBV variants includes point muta-
tions in the BCP, which overlaps with the open reading frame for 
gene X and regulates expression of both HBeAg and the core pro-
tein (  24  ). The most frequent BCP mutation is a double mutation 
involving an A to T substitution at nucleotide 1762 and a G to A 
substitution at nucleotide 1764 (hereafter referred to as BCP 
A1762T/G1764A), which results in a substantial decrease in HBeAg 
expression but enhanced viral genome replication in vitro (  25  ). 
  Although many cross-sectional and case  –  control studies 
(  6  ,  8  ,  9  ,  17  ,  26    –    29  ) have suggested that HBV genotype and the pre-
core and BCP mutants have a substantial impact on the progres-
sion of chronic hepatitis B, none has, to our knowledge, examined 
the prevalence of these variants in the general population of HBV 
hyperendemic areas. In addition, the incidence of HCC in associa-
tion with HBV genotype and mutants has yet to be estimated in a 
community-based study with long-term follow-up. Our aim was to 
examine the prevalence of HBV genotype and precore and BCP 
mutants and their association with HCC risk after adjusting for 
well-known host and viral risk factors. 
    Participants and Methods 
    Cohort Enrollment and Subject Flow 
  This study included participants in the established REVEAL-HBV 
cohort study, a community-based prospective cohort study for 
which the goal is to investigate the association between viral factors 
and the risk of liver diseases, including HCC. The enrollment of the 
study cohort has been described previously (  4  ). Briefly, as shown in 
Figure 1, all 89    293 men and women between the ages of 30 and 65 
years who were living in seven townships in Taiwan were invited by 
mail and telephone to participate in the study. A total of 23    820 resi-
dents (27%) agreed to participate and provided written informed 
consent for us to conduct interviews, health examinations, and blood 
collections at study entry and follow-up. We carried out laboratory 
tests, including tests for virological and serological biomarkers; 
medical record review; and computerized data linkage to national 
health profiles for each participant. All 23    820 participants were free 
of HCC at study entry as confirmed by baseline health examinations 
(abdominal ultrasonography and alpha-fetoprotein testing) and 
examination of records at the Taiwan National Cancer Registry. 
Hepatitis B surface antigen (HBsAg)  –  positive participants (n = 4155) 
were scheduled for follow-up every 6  –  12 months with abdominal 
ultrasonography and a medical examination. After excluding partici-
pants with antibodies against hepatitis C virus (anti-HCV, n = 191), 
unknown anti-HCV antibody status (n = 4), undetectable baseline 
    CONTEXT AND CAVEATS 
    Prior knowledge 
  The risk of hepatocellular carcinoma (HCC) increases with increas-
ing level of hepatitis B virus (HBV) in serum. However, it is unclear 
whether HBV genotype and common variants in the precore and 
basal core promoter (BCP) regions contribute to the risk of HCC.   
    Study design 
  The incidence of HCC in association with HBV genotype and 
mutants was estimated for participants in a community-based 
cohort study with long-term follow-up.   
    Contribution 
  HBV genotype C and the BCP A1762T/G1764A mutant were inde-
pendent risk factors for HCC, and the precore G1896A mutant was 
associated with a decreased risk of HCC.   
    Implications 
  HBV genotype and precore and BCP mutation status, in addition to 
other factors, including age, sex, and HBV viral load, may help iden-
tify those who are at an increased risk for liver disease progression.   
    Limitations 
  The analysis of HBV genotype and mutants was based on a single 
blood sample obtained at study entry. Uncommon mutations were 
detected but not analyzed because of small sample sizes. 
    From the Editors       
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serum HBV DNA levels (n = 882), or inadequate blood sample for 
HBV genotyping (n = 316), a total of 2762 participants (all with 100 
copies or more of HBV DNA per milliliter) were included in this 
analysis. Of these, only those with 10  4   copies or more of HBV DNA 
per milliliter, the detection limit of the nested polymerase chain 
reaction (PCR) assay for mutant types (n = 1526), were tested for the 
precore 1896 and BCP 1762/1764 mutations. This study was 
approved by the Institutional Review Board of the College of Public 
Health, National Taiwan University in Taipei, Taiwan.   
    Interview and Blood Collection 
  All of the participants were interviewed in person at enrollment by 
public health nurses who used a structured questionnaire to obtain 
information on sociodemographic characteristics, dietary habits, 
histories of cigarette smoking and alcohol consumption, personal 
medical and surgical history, family history of cancers and other 
major diseases, and gynecologic information (for female subjects). 
A 10-mL blood sample was collected from each participant at study 
entry and at each follow-up examination (every 6 to 12 months, 
maximum of 23 follow-ups). The samples were fractionated on the 
day of collection into several vials of plasma and buffy coat and the 
fractions were stored at     70°C.   
    Laboratory Tests 
  We used commercially available kits (all from Abbott Laboratories, 
North Chicago, IL) to test serum samples for HBsAg, HBeAg, and 
alpha-fetoprotein by radioimmunoassay and for anti-HCV by 
enzyme immunoassay. Serum alanine aminotransferase (ALT) lev-
els  —  a marker of liver inflammation  —  were measured with the use of 
a serum chemistry autoanalyzer (model 736, Hitachi, Tokyo, Japan) 
and commercially available reagents (Biomérieux, Marcy L  ’  Etoile, 
France). 
  HBV DNA was extracted from 200 mL of each plasma sample 
with the use of a High Pure Viral Nucleic Acid Kit (Roche 
Diagnostics Applied Science, Mannheim, Germany) as per the 
manufacturer’s instructions. The viral titer and genotype of HBV 
were determined by a real-time PCR-based method that used 
ﬂ  uorescent hybridization probes and a LightCycler PCR machine 
(Roche Diagnostics Applied Science). The method consisted of 
two steps that were carried out in a single tube: the ﬁ  rst step 
used real-time PCR to quantify the viral DNA and the second 
step used melting curve analysis of the ﬁ   nal PCR product to 
genotype the virus. Details of the design and experimental condi-
tions of this assay have been published (  30  ). The sequences for 
the primer set used for amplicon ampliﬁ   cation were 5  ′  -
CCGATCCATACTGCGGAAC-3  ′   (forward) and 5 ′  -GCAGAGG  -
TGAAGCGAAGTGCA-3  ′   (reverse). The sequences for the 
probes used for generating the ﬂ  uorescent signals were ﬂ  uores-
cein  –  5  ′  -TCTGTGCCTTCTCATCTGCCGGACC-3  ′  -P 
(anchor probe, with its 3  ′   end phosphorylated to prevent probe 
elongation by   Taq   polymerase during PCR) and 5  ′  -TCTT-
TACGCGGACTCCCC-LC-Red640-3  ′   (sensor probe) (TIB 
MOLBIOL, Berlin, Germany). This assay showed a broad linear 
distribution for HBV titers that ranged from 10  2   to 10 
11   copies/mL 
      Figure 1    .       Flow of participants in the study. 
HBsAg = hepatitis B surface antigen; HBV = hep-
atitis B virus; anti-HCV = antibodies against 
hepatitis C virus; BCP = basal core promoter; 
HCC = hepatocellular carcinoma; PCR = poly-
merase chain reaction      .       jnci.oxfordjournals.org    JNCI | Articles 1137
and a lower detection limit of 1  –  5 × 10 
2   copies/mL (  30  ). The 
results of this assay were strongly correlated (  P   < .001 based on 
linear regression analysis) with the results of three commercial 
assays for HBV titer: SuperQuant assay (National Genetics 
Institute, Culver City, CA;   R    2   = .9866), the Amplicor assay (Roche 
Diagnostics, Indianapolis, IN;   R    2   = .983), and the bDNA assay 
(Chiron Corporation, Emeryville, CA;   R    2   = .999). For genotype 
determination by melting curve analysis, different genotypes of 
HBV showed distinct melting temperature (Tm) values, that is, 
59.1  –  62.7°C for genotype B and 53.0  –  56.6°C for genotype C 
(  30  ). Our genotyping results yielded an inconsistency rate of less 
than 1% when compared with the gold standard method of direct 
sequencing and phylogenetic analysis (  30  ). Samples that gave 
equivocal genotyping results by the melting curve analysis were 
subjected to DNA sequence analysis of the pre-S region of the 
HBV genome with the use of ABI PRISM BigDye sequencing 
kits and an ABI 3100 Genetic Analyzer (all from Applied 
Biosystems, Foster City, CA), according to the manufacturer’s 
instructions as previously described (  30  ), and the sequence 
was then processed for phylogenetic analysis for genotype 
determination. 
  Precore 1896 and BCP 1762/1764 mutations were assayed 
using direct DNA sequence analysis. PCR ampliﬁ  cation  was 
ﬁ  rst conducted with the use of a T3 Thermocycler (Biometra, 
Whatman Corp., Gottingen, Germany) in a 15-mL reaction 
volume that contained either 4 mL of extracted serum DNA 
(for the ﬁ  rst PCR) or 1 mL of a 20-fold dilution of the ﬁ  rst 
PCR product (for the nested PCR) as the template DNA, 
30 ng of each primer, and PCR buffer (20 mM Tris  –  HCl [pH 
8.4], 50 mM KCl, 1.66 mM MgCl  2  , 200 mM of each dNTP, and 
0.4 U Platinum   Taq   polymerase) (Invitrogen, Carlsbad, CA). 
The nested primer sets used for the PCR ampliﬁ  cation were 
designed to ﬂ  ank the BCP and precore region of HBV genome: 
5  ′  -ACTCTTGGACTYTCAGCAATG-3  ′   (Y = C or T, forward 
primer) and 5  ′  -GTCAGAAGGCAAAAAAGAGAG-3  ′   (reverse 
primer) for the ﬁ   rst PCR reaction, and 5  ′  -TCTCA  GCA-
ATGTCAACGACCG-3  ′   (forward primer) and 5  ′  -AGAGAGT-
AACTCCACAGAWGCTC-3  ′   (W = A or T, reverse primer) 
for the nested PCR reaction. The thermal cycler conditions 
consisted of 5 minutes at 95°C, followed by 35 cycles of 95°C 
for 45 seconds, 60°C for 45 seconds, and 72°C for 30 seconds, 
followed by a ﬁ  nal extension at 72°C for 10 minutes. The integ-
rity of the ﬁ  nal PCR products was checked by agarose gel elec-
trophoresis, and the PCR products were then used as template 
for subsequent direct sequencing analysis as described above.   
    Follow-up and Ascertainment of HCC 
  Incident HCC cases were detected by follow-up health examina-
tions, which included abdominal ultrasonography and serological 
tests for ALT and alpha-fetoprotein, and by computerized data 
linkage with profiles of the National Cancer Registry in Taiwan 
from January 1, 1991, through June 30, 2004. Data linkage with 
the profiles on the national death certification system was also 
performed to identify cases not registered in the cancer registry 
system. During 33    747 person-years of follow-up, 153 incident 
HCC cases were ascertained using the following criteria among 
the 2762 subjects who qualified for inclusion in this analysis set: a 
histopathologic examination (64 cases), a positive lesion detected 
by at least two different imaging techniques (abdominal ultraso-
nography, angiogram, and/or computed tomography, 81 cases), 
or a positive lesion by one imaging technique and a serum alpha-
fetoprotein concentration of 400 ng/mL or higher (32 cases). 
Twenty-four cases were ascertained based on more than one 
criterion.   
    Statistical Analysis 
  Trends in the age-specific prevalence of HBV genotype C and 
precore G1896A and BCP A1762T/G1764A mutants were 
evaluated using the Cochran  –  Armitage trend test. Incidence 
rates of HCC by genotype and precore and BCP mutation status 
were calculated by dividing the number of incident HCC cases 
by the person-years of follow-up. The person-years of follow-up 
for each study subject were determined from the date of recruit-
ment to the date of HCC detection, the date at death, or the last 
date of linked data available from the National Cancer Registry 
(up to June 30, 2004), whichever came first. Study subjects who 
were free of HCC at death or at the end of follow-up were 
censored. 
  A Cox proportional hazards model was used to estimate the 
risk of HCC associated with HBV genotype and precore and 
BCP mutants after adjustment for other risk factors for HCC, 
including sex, age at recruitment, cigarette smoking status, alco-
hol consumption status, serum levels of HBV DNA and ALT, 
and liver cirrhosis at enrollment. A 10-year interval and a base-
10 logarithm were used for the cut point of age at recruitment 
and HBV DNA level, respectively, for ease of clinical applica-
tion. The cut points for serum ALT level were chosen on the 
basis of our previous analysis using a trajectory model (  31  ) that 
classiﬁ   ed long-term ALT changes of participants into three 
groups. The trajectory model was used to identify subgroups in 
the population that have similar patterns of changes of serum 
ALT levels over time (  32  ). Multivariable-adjusted hazard ratios 
(HR  adj  s) and 95% conﬁ  dence intervals (CIs) were derived for 
each risk factor. The assumption of proportionality for the Cox 
analysis was tested by examining the interaction between the 
year of follow-up with HBV genotype and mutants, and no vio-
lation of this assumption was observed. The hazard ratio of 
HCC by HBV DNA   and ALT levels was further investigated 
in subgroup analyses by using a Cox pro  portional hazards model 
with stratiﬁ  cation according to HBV genotypes. The combined 
effects of HBV genotype and precore 1896 and BCP 1762/1764 
mutants on the risk of HCC were further investigated using a 
Cox proportional hazards regression model. Statistical signiﬁ  -
cance level was deﬁ  ned as   P   < .05 by two-tailed tests. SAS soft-
ware (version 8.01; SAS Institute Inc., Cary, NC) was used for 
all analyses.     
    Results 
    Characteristics of the Study Cohort 
  As shown in   Table 1  , the majority of the study participants were 
male; 68.8% of study participants did not smoke cigarettes and 
88.6% did not consume alcohol. Most participants were HBeAg 
seronegative, had very low serum ALT levels (<15 U/L), had 1138   Articles | JNCI  Vol. 100, Issue 16  |  August 20, 2008
elevated serum HBV DNA (  ≥  10 
4   copies/mL), and had no evidence 
of liver cirrhosis by ultrasonography.           
    Prevalence of HBV Genotype and Mutants 
  Overall, 1773 subjects (64.2%) were infected with HBV genotype 
B alone, 889 (32.2%) were infected with genotype C alone, and 
100 (3.6%) were infected with both genotypes (  Table 2  ). The 
precore and BCP mutations were determined only in subjects 
whose baseline HBV DNA level was 10  4   copies/mL or higher (n = 
1526). As shown in   Table 2  , the most common precore variant was 
the 1896A mutation (47.0%), and the most common BCP 
1762/1764 variant was the double wild type (ie, A1762/G1764) 
(57.4%). Several less common BCP 1762/1764 variants were also 
observed, each of which had a prevalence of less than 6%. During 
follow-up, HCC developed in 6 (22.2%) of 27 subjects with the 
A1762/A1764 variant, 8 (9.8%) of 82 subjects with the H1762/
H1764 variant, and 6 (7.7%) of 78 subjects with the D1762/D1764 
variant.         
  As shown in   Figure 2  , the prevalence of HBV genotype C 
remained constant across all four age groups in both men (  P    trend   = 
.44) and women (  P    trend   = .35). A higher proportion of women than 
men were infected with HBV genotype C (36.1% vs 29.3%;   P   < 
.001). The prevalence of the precore G1869A mutant increased 
with age in both males and females (  P    trend   < .001 for both). The 
prevalence of the BCP A1762T/G1764A double mutant also 
increased with age (  P    trend   = .02 for females and   P    trend   = .003 for 
males).                 
  The prevalence of the precore G1896A mutant was higher in 
participants infected with HBV genotype B than in those infected 
with HBV genotype C (57.5% vs 25.8%;   P   < .001). The prevalence 
of the BCP A1762T/G1764A double mutant was higher in partici-
pants infected with HBV genotype C than in those infected with 
HBV genotype B (43.0% vs 21.4%;   P   < .001). Participants with 
genotype C infection had a higher viral load than those with geno-
type B infection. The proportion of participants with a plasma 
HBV DNA level of at least 10  6   copies/mL was 17.6% for those 
with genotype B infection compared with 33.8% for those with 
genotype C infection (  P   < .001).   
    HCC Incidence Rates by HBV Genotype and Precore and 
BCP Mutations 
  Among participants with a detectable baseline level of HBV 
DNA, the HCC incidence rates per 100    000 person-years for 
genotypes B and C were 305.6 (95% CI = 236.9 to 388.1) and 
785.8 (95% CI = 626.8 to 972.9), respectively (  Table 3  ). Among 
participants with a baseline HBV DNA level of at least 10  4   cop-
ies/mL, those with the precore wild-type G1896 variant had a 
higher incidence of HCC than those with the G1896A mutant 
variant (955.5 [95% CI = 749.0 to 1201.4] vs 269.4 [95% CI = 
172.6 to 400.9] per 100    000 person-years), and those with the 
BCP A1762T/G1764A  double mutant had a higher incidence of 
  Table 2    .       Prevalence of hepatitis B virus genotype and precore 
1896 and BCP 1762/1764 mutants in the study cohort  *     
    HBV characteristic No. (%)   
    Genotype  
         B 1773 (64.2) 
         B and C 100 (3.6) 
         C 889 (32.2) 
  Precore 1896    †     
         G (wild type) 641 (42.0) 
         A (predominant mutant) 717 (47.0) 
         G and A (mixed type) 168 (11.0) 
  BCP (1762/1764)    †  ,      ‡     
         A/G (wild type/wild type) 876 (57.4) 
         T/A (predominant mutant/predominant mutant) 436 (28.6) 
         H/A 6 (0.4) 
         H/H 82 (5.4) 
         A/A 27 (1.8) 
         A/H 11 (0.7) 
         A/T 1 (0.1) 
         H/G 3 (0.2) 
         G/A 2 (0.2) 
         T/G 2 (0.1) 
         H/C 1 (0.1) 
         G/H 1 (0.1) 
         D/D 78 (5.1)   
    *     Some percentages do not total 100 because of rounding. HBV = hepatitis B 
virus; BCP = basal core promoter.   
      †       Among subjects with HBV DNA levels of at least 10  4   copies/mL 
(n = 1526).   
      ‡       H = both wild type and predominant mutants were detectable; D = deletion. 
Categories other than wild type and predominant mutant were classed as 
mixed type.     
  Table 1    .       Baseline characteristics of the study cohort (N = 2762)  *     
    Variable No. (%)   
    Sex  
         Female 1187 (43.0) 
         Male 1575 (57.0) 
  Age, y  
         30  –  39 927 (33.6) 
         40  –  49 785 (28.4) 
         50  –  59 798 (28.9) 
         60  –  65 252 (9.1) 
  Cigarette smoker    †     
         No 1898 (68.8) 
         Yes 862 (31.2) 
  Alcohol drinker    ‡     
         No 2442 (88.6) 
         Yes 314 (11.4) 
  Serum ALT level, U/L  
         <15 1659 (60.1) 
         15  –  44 933 (33.8) 
           ≥  45 170 (6.2) 
  HBeAg serostatus  
         Negative 2235 (80.9) 
         Positive 527 (19.1) 
  HBV DNA level, copies/mL  
         100  –  9999 1013 (36.7) 
         10    000  –  99    999 746 (27.0) 
         100    000  –  999    999 380 (13.8) 
           ≥  10  6 623  (22.6) 
  Liver cirrhosis at entry  
         No 2692 (97.5) 
         Yes 70 (2.5)   
    *     Some percentages do not total 100 because of rounding. ALT = alanine 
aminotransferase; HBeAg = hepatitis B virus e antigen; HBV = hepatitis B 
virus.   
      †       Data not available for two subjects.   
      ‡       Data not available for six subjects.     jnci.oxfordjournals.org    JNCI | Articles 1139
HCC than those with BCP A1762/G1764 wild type (1149.2 [95% 
CI = 872.6 to 1485.6] vs 358.7 [95% CI = 255.1 to 490.4] per 
100    000 person-years).           
    HCC Risk Adjusted for Other Covariates 
  Overall, infection with genotype C was associated with a higher 
risk of HCC than infection with genotype B, with an adjusted 
hazard ratio of 2.35 (95% CI = 1.68 to 3.30;   P   < .001) (  Table 4  ). 
Among participants with a baseline HBV DNA level of 10  4   
copies/mL or greater, genotype C infection was also associated 
with a higher risk of HCC, with an adjusted hazard ratio of 
1.76 (95% CI = 1.19 to 2.61;   P   = .005). The adjusted hazard 
ratio of HCC for the BCP A1762T/G1764A mutation vs wild 
type was 1.73 (95% CI = 1.13 to 2.67;   P   = .013). By contrast, the 
precore G1896A mutation was associated with a lower risk of 
HCC than the precore wild type (HR  adj   = 0.34, 95% CI = 0.21 
to 0.57;   P   < .001).           
    Risk of HCC According to HBV DNA and Serum ALT 
Levels and Stratified by HBV Genotype 
  Among participants infected with HBV genotype B, the hazard 
ratio of developing HCC was 1.48 (95% CI = 0.67 to 3.26) for 
those with DNA levels of 10  000–99  999 vs 100–9999 copies/
mL, 2.81 (95% CI = 1.27 to 6.19) for those with 100    000  –  999    999 
vs 100  –  9999 copies/mL, and 4.63 (95% CI = 2.17 to 9.87) for 
those with 10  6   copies/mL or more vs 100  –  9999 copies/mL. 
Among participants infected with HBV genotype C, the 
corresponding hazard ratios were 2.46 (95% CI = 1.06 to 5.72), 
4.71 (95% CI = 2.12 to 10.46), and 5.19 (95% CI = 2.62 to 
10.31), respectively. There was no statistically significant 
interaction between HBV genotype and baseline HBV DNA 
level (  P   = .51). 
  Among participants infected with HBV genotype B, the hazard 
ratios of HCC for those with baseline ALT levels of 15  –  44 U/L or 
45 U/L or more vs those with ALT levels less than 15 U/L were 
1.42 (95% CI = 0.83 to 2.45) and 1.00 (95% CI = 0.40 to 2.52), 
respectively. Among participants infected with HBV genotype C, 
the corresponding hazard ratios were 2.61 (95% CI = 1.46 to 4.66) 
and 3.04 (95% CI = 1.48 to 6.22), respectively. There was no sta-
tistically signiﬁ  cant interaction between HBV genotype and base-
line ALT level (  P   = .21).   
    Incidence and Risk of HCC for Combinations of HBV 
Genotype and Mutants 
  Finally, we examined the risk of HCC associated with combina-
tions of HBV genotype, the precore G1896A mutant, and the BCP 
  Table 3    .       Incidence rate of HCC by hepatitis B virus genotype and precore and BCP mutants  *     
    Genotype or mutant No. of cohort members Person-years of follow-up No. of HCC cases
Incidence rate per 100    000 
person-years (95% CI)   
    HBV genotype  
         B 1773 21    921.9 67 305.6 (236.9 to 388.1) 
         B and C 100 1235.0 2 161.9 (19.6 to 585.0) 
         C 889 10    689.7 84 785.8 (626.8 to 972.9) 
  Precore 1896    †     
         Wild type 641 7639.8 73 955.5 (749.0 to 1201.4) 
         G1896A 717 8908.4 24 269.4 (172.6 to 400.9) 
         Mixed type 168 1943.4 24 1234.9 (791.3 to 1837.5) 
  BCP 1762/1764    †     
         Wild type 876 10872.3 39 358.7 (255.1 to 490.4) 
         A1762T/G1764A 436 5047.0 58 1149.2 (872.6 to 1485.6) 
         Mixed type 214 2572.2 24 933.1 (597.8 to 1388.3)   
    *     HCC = hepatocellular carcinoma; CI = confidence interval; HBV = hepatitis B virus; BCP = basal core promoter.   
      †       Among subjects with HBV DNA levels of at least 10 
4   copies/mL (n = 1526).     
   
  Figure 2    .        Prevalence of hepatitis B virus genotype and precore G1896A 
and BCP A1762T/G1764A mutants by age at recruitment.   A  ) Female 
participants.   B  ) Male participants. BCP = basal core promoter.   P    trend   
(two-sided) values are from the Cochran  –  Armitage test.       1140   Articles | JNCI  Vol. 100, Issue 16  |  August 20, 2008
double mutants. Participants who were infected with HBV geno-
type C, had the wild-type precore 1896 variant, and had the BCP 
A1762T/G1764A double mutation had the highest incidence of 
HCC (2254.2 per 100    000 person-years), with an adjusted hazard 
ratio of 2.99 (95% CI = 1.57 to 5.70,   P   < .001) relative to partici-
pants who were infected with HBV genotype B and wild type for 
the precore 1896 and BCP 1762/1764 variants (  Table 5  ). By con-
trast, participants who were infected with HBV genotype B, had 
the precore G1896A variant, and had the wild-type BCP 1762/1764 
variant had the lowest incidence of HCC (173.9 per 100    000 per-
son-years), with an adjusted hazard ratio of 0.20 (95% CI = 0.09 to 
0.46,   P   < .001) relative to participants who were infected with 
HBV genotype B and wild type for the precore 1896 and BCP 
1762/1764 variants.             
  Table 4    .       Cox proportional hazards regression analysis of HCC predictors  *     
    Variable
All participants (N = 2762)
Participants with 10 
4   copies or more HBV DNA 
per milliliter at entry (n = 1526) 
  Crude HR 
(95% CI)   P       †  
Adjusted HR 
(95% CI)    ‡     P       †  
Crude HR 
(95% CI)   P       †  
Adjusted HR 
(95% CI)  §   P       †      
    Sex  
         Female 1.00 (referent) 1.00 (referent) 1.00 (referent) 1.00 (referent)  
         Male 3.38 (2.26 to 5.07) <.001 2.25 (1.41 to 3.60) <.001 3.86 (2.43 to 6.13) <.001 2.93 (1.72 to 5.01) <.001 
  Age, y  
         30  –  39 1.00 (referent) 1.00 (referent) 1.00 (referent) 1.00 (referent)  
         40  –  49 3.93 (2.16 to 7.15) <.001 4.23 (2.31 to 7.74) <.001 4.10 (2.09 to 8.05) <.001 4.73 (2.39 to 9.36) <.001 
         50  –  59 5.81 (3.26 to 10.34) <.001 6.46 (3.60 to 11.60) <.001 6.07 (3.17 to 11.62) <.001 6.74 (3.46 to 13.13) <.001 
           ≥  60 8.89 (4.70 to 16.83) <.001 9.45 (4.94 to 18.08) <.001 8.53 (4.11 to 17.70) <.001 10.81 (5.13 to 22.80) <.001 
  Cigarette smoker  
         No 1.00 (referent) 1.00 (referent) 1.00 (referent) 1.00 (referent)  
         Yes 1.86 (1.35 to 2.56) <.001 1.16 (0.80 to 1.68) .44 1.97 (1.37 to 2.81) <.001 1.05 (0.69 to 1.59) .83 
  Alcohol drinker  
         No 1.00 (referent) 1.00 (referent) 1.00 (referent) 1.00 (referent)  
         Yes 2.77 (1.92 to 4.00) <.001 1.51 (1.01 to 2.26) .044 2.94 (1.95 to 4.43) <.001 1.30 (0.83 to 2.05) .25 
  Serum ALT level, 
  U/L
 
         <15 1.00 (referent) 1.00 (referent) 1.00 (referent) 1.00 (referent)  
         15  –  44 3.30 (2.29 to 4.75) <.001 1.95 (1.33 to 2.86) <.001 2.95 (1.93 to 4.49) <.001 1.82 (1.16 to 2.84) .009 
           ≥  45 6.63 (4.11 to 10.68) <.001 1.83 (1.07 to 3.11) .026 5.23 (3.11 to 8.80) <.001 1.96 (1.10 to 3.50) .023 
  Cirrhosis at study 
  entry
 
         No 1.00 (referent) 1.00 (referent) 1.00 (referent) 1.00 (referent)  
         Yes 19.22 (13.15 to 28.11) <.001 7.52 (4.97 to 11.39) <.001 12.61 (8.05 to 19.77) <.001 4.49 (2.69 to 7.49) <.001 
  HBV DNA level, 
  copies/mL
 
         100  –  9999 1.00 (referent) 1.00 (referent)   –   –  
         10    000  –  99    999 1.54 (0.88 to 2.69) .13 1.76 (1.00 to 3.12) .05 1.00 (referent) 1.00 (referent)  
         100    000  –  999    999 4.04 (2.38 to 6.86) <.001 3.44 (1.99 to 5.94) <.001 2.40 (1.39 to 4.13) .002 1.61 (0.91 to 2.84) .10 
           ≥  10  6  5.28 (3.29 to 8.45) <.001 4.42 (2.71 to 7.20) <.001 3.00 (1.84 to 4.90) <.001 1.50 (0.88 to 2.58) .14 
  HBV genotype  
         B 1.00 (referent) 1.00 (referent) 1.00 (referent) 1.00 (referent)  
         C 2.59 (1.88 to 3.57) <.001 2.35 (1.68 to 3.30) <.001 2.63 (1.83 to 3.77) <.001 1.76 (1.19 to 2.61) .005 
         B and C 0.53 (0.13 to 2.16) .38 0.65 (0.16 to 2.66) .55 0.35 (0.05 to 2.55) .30 0.33 (0.04 to 2.40) .27 
  Precore 1896  
         Wild type 1.00 (referent) 1.00 (referent)  
         G1896A     ||       ||           0.28 (0.18 to 0.44) <.001 0.34 (0.21 to 0.57) <.001 
         Mixed type 1.30 (0.82 to 2.06) .27 1.18 (0.71 to 1.96) .52 
  BCP 1764/1764  
         Wild type 1.00 (referent) 1.00 (referent)  
         A1762T/G1764A     ||       ||           3.22 (2.14 to 4.83) <.001 1.73 (1.13 to 2.67) .013 
         Mixed type 2.61 (1.57 to 4.34) <.001 1.04 (0.59 to 1.84) .88   
    *       P   values (two-sided) were from Cox proportional hazards models. HCC = hepatocellular carcinoma; HBV = hepatitis B virus; HR = hazard ratio; CI = confidence 
interval; ALT = alanine aminotra  nsferase;   –   = not applicable; BCP = basal core promoter.   
      †         P   values (two-sided) were from Cox proportional hazards models.   
      ‡       Multivariable-adjusted model controlled for the following variables: sex, age, cigarette smoking, alcohol drinking, serum ALT level, cirrhosis at study entry, HBV 
DNA level, and HBV genotype.   
    §     Multivariable-adjusted model for sex, age, cigarette smoking, alcohol drinking, serum ALT level, cirrhosis at study entry, HBV DNA level, HBV genotype, and 
precore and BCP mutants.   
      ||       Not included due to lack of data on HBV mutants for subjects with entry HBV DNA levels of less than 10 
4   copies/mL.     jnci.oxfordjournals.org    JNCI | Articles 1141
    Discussion 
  The role of HBV genotype and mutants in disease progression 
continues to be of great interest. Unlike in hepatitis C virus 
(HCV) infection, the relationship between different HBV 
genotypes and risk of future disease is not well established. 
In this analysis of a subset of the REVEAL-HBV study cohort, 
we found that the majority of participants (64.2%) were infected 
with genotype B virus alone, consistent with other studies 
from Taiwan (  7  ,  9  ). Among participants with baseline HBV 
DNA levels of 10 
4   copies or more per milliliter, the prevalences 
of precore and BCP typical mutants were 47.0% and 28.6%, 
respectively, at study entry and increased with age. As has been 
described by other studies (mostly from Asia), we also found 
that HBV genotype C infection was associated with a higher 
risk of HCC than HBV genotype B infection; in addition, we 
found that the BCP A1762T/G1764A mutant was associated 
with an increased risk of HCC compared with the double wild-
type variant, whereas the precore G1896A mutation was associ-
ated with a decreased risk of HCC compared with the wild-type 
variant. 
  Our ﬁ  nding that the precore G1896A mutation was associated 
with a lower risk of HCC compared with wild-type virus appears 
to be at odds with several early case reports that found an associa-
tion between the precore stop mutation and a marked increase in 
viral virulence and the development of fulminant hepatitis (  21  ,  22  ). 
However, another study (  33  )  —  in HBeAg-negative, HBV-infected 
persons  —  found that infection with HBV containing wild-type 
precore was associated with more hepatic inﬂ  ammation  and 
ﬁ   brosis than infection with precore mutant HBV. Also, severe 
clinical manifestations of chronic hepatitis in patients with abrupt 
elevation of serum ALT level (>200 U/L) are more frequently 
observed in those with the precore wild type than G1896A muta-
tion (  34  ). The negative association between the precore G1896A 
mutant and HCC that we observed in this study after adjustment 
for sex, age, cigarette smoking status, alcohol consumption status, 
serum ALT level, and cirrhosis at study entry, as well as HBV 
genotype, viral load, and BCP mutant, suggested that the precore 
G1896A mutation was associated with a low risk of HCC. 
  Several mechanisms of hepatocarcinogenesis relating to the 
BCP A1762T/G1764A mutant have been hypothesized. It has 
been proposed that the BCP A1762T/G1764A mutation may 
enhance HBV virulence by increasing host immune response 
(  25  ,  35  ,  36  ), increasing viral replication (  37    –    42  ), or altering the cod-
ing region for the X antigen (  6  ,  18  ,  43  ). Circulating HBeAg may 
interfere with the clearance of infected hepatocytes and promote 
immune tolerance (  25  ,  36  ). By diminishing circulating HBeAg, 
mutant BCP may augment the host immune response to HBV-
infected hepatocytes, hence increasing hepatocyte apoptosis and 
regeneration, which leads to liver injury (  25  ,  36  ). The BCP muta-
tion appears to enhance the efﬁ  ciency of viral replication either by 
modulating the relative levels of the precore and core RNAs or by 
creating a hepatocyte nuclear factor 1 transcription factor binding 
site (  42  ). The X antigen of HBV has potential transactivation 
activity for both viral and host genes, and it has been shown to 
interact directly with p53 and the DNA repair enzyme XAP-1 (  44  ). 
Mutations in the BCP region, which overlaps the coding sequence 
for the X antigen of HBV, may result in amino acid changes 
K130M and V131I in the X antigen. These amino acid changes 
may interfere with cell growth control and DNA repair and may 
cause HCC (  44  ,  45  ). In a multivariable Cox regression analysis, we 
found that the BCP A1762T/G1764A mutation was associated 
with an increased risk of HCC independent of viral load and other 
risk factors. Therefore, other mechanisms of hepatocarcinogene-
sis, such as the alteration of transactivation capability of X antigen 
induced by amino acid changes related to the BCP A1762T/
G1764A mutation, should be considered in future studies. 
  The association between genotype C infection and a higher 
disease progression and HCC risk has been reported previously 
(  9  ,  16  ,  46  ), but the reason for this association remains poorly under-
stood. Individuals infected with genotype C HBV might have a 
higher circulating viral load, as indicated by our analysis (33.8% of 
genotype C  –  infected participants had 10  6   copies or more of HBV 
DNA per milliliter of plasma compared with 17.6% of genotype 
B  –  infected participants). However, in the Cox regression analysis 
shown in   Table 4  , the hazard ratio of HCC for genotype C com-
pared with genotype B was similar with or without adjustment for 
the viral load and other risk factors, suggesting that the association 
  Table 5    .       Incidence rates and hazard ratios of HCC for the combination of HBV genotype and precore and BCP variants among the 1526 
subjects with at least 10 
4   copies/mL HBV DNA  *     










No. of HCC 
cases
HCC incidence 
(per 100    000 
person-years)
Adjusted HR    †     
(95% CI)   P      ‡       
    B Wild type Wild type 198 2404.8 14 582.2 1.0 (referent)  
  B Wild type A1762T/G1764A 82 950.1 9 947.3 1.35 (0.58 to 3.12) .48 
  B G1896A Wild type 413 5175.0 9 173.9 0.20 (0.09 to 0.46)    †   <.001 
  B G1896A A1762T/G1764A 110 1319.9 7 530.3 0.62 (0.25 to 1.54) .30 
  C Wild type Wild type 129 1633.2 6 367.4 0.73 (0.28 to 1.89) .51 
  C Wild type A1762T/G1764A 115 1242.1 28 2254.2 2.99 (1.57 to 5.70)    †   <.001 
  C G1896A Wild type 41 497.3 4 804.3 1.38 (0.45 to 4.20) .57 
  C G1896A A1762T/G1764A 73 911.2 2 219.5 0.36 (0.08 to 1.59) .18   
    *     HCC = hepatocellular carcinoma; HBV = hepatitis B virus; BCP = basal core promoter; HR = hazard ratio; CI = confidence interval.   
      †       Adjusted for sex and age at recruitment.   
      ‡         P   values (two-sided) were from Cox proportional hazards models.     1142   Articles | JNCI  Vol. 100, Issue 16  |  August 20, 2008
between genotype C and the increased risk of HCC was not con-
founded by HBV viral load. Several studies (  8  ,  26  ) have also 
revealed that individuals infected with HBV genotype C are more 
likely to develop the BCP double mutant than those infected with 
genotype B. It has been suggested that the BCP double mutant, 
rather than HBV genotype C per se, is the primary risk factor for 
liver cancer (  8  ,  47  ). However, in this study we demonstrated that 
both genotype C and BCP A1762T/G1764A mutation status are 
independent risk factors for the development of 
HCC. Therefore, the association between HBV genotype C and 
HCC risk cannot be totally explained by the appearance of BCP 
mutants. 
  One strength of this study is that all virological factors were 
determined on samples that were collected before the development 
of HCC from subjects who were not treated with any anti-HBV 
therapies. Our study is also unique because of the large sample 
size, because both men and women were enrolled, and because it 
was a prospective population-based study. Previous studies of 
HBV genotype and/or mutants and disease progression have been 
limited because they were hospital based and subject to selection 
bias, had a small sample size, included only men, or had a short 
follow-up. 
  There are also some limitations that should be considered when 
interpreting these data. First, our analysis of HBV genotype and 
mutants was based on a single blood sample obtained at study 
entry; thus, we could not assess the effect of changes in HBV geno-
type or mutation status on the development of HCC. However, 
the cross-sectional age-speciﬁ  c prevalence of these viral factors 
(  Figure 2  ) suggests that HBV genotype is stable across age groups 
and that both the HBV precore and the BCP double mutants 
accumulated with increasing age. Thus, to the extent that HBV 
mutants emerged after study entry, the associations between each 
HBV mutations and the risk of HCC would be underestimated. 
Second, although we detected several other mutations in addition 
to the common ones we analyzed, small sample sizes hindered a 
further analysis of them. These mutants, although uncommon, 
may provide clues for further studies on the role of BCP mutants 
during HBV-associated hepatocarcinogenesis. 
  In conclusion, HBV genotype C and the BCP A1762T/G1764A 
mutant were independent risk factors for HCC, and the precore 
G1896A mutant was associated with a decreased risk of HCC. 
Consistent with our previous report (  4  ), we found that the associa-
tion between HBV DNA level and HCC was independent of other 
factors, including HBV genotype and precore and BCP mutation 
status. These genetic features of HBV, in addition to age, sex, 
HBV viral load, and serum ALT levels, may help identify those 
who are at an increased risk for liver disease progression and would 
therefore potentially beneﬁ  t from early interventions, such as reg-
ular screening to detect disease progression, and treatment.   
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